Navigation Links
NexMed Announces Completion of Patient Enrollment in Two Pivotal,Phase 3 Studies for Anti-Fungal Product

EAST WINDSOR, N.J.--(BUSINESS WIRE)--July 9, 2007 - NexMed, Inc. (NASDAQ: NEXM), a developer of innovative transdermal treatments based on the NexACT(R) drug delivery technology, today announced that Novartis Pharma AG has completed patient enrollment for Phase III clinical trials for NM100060, a topical treatment for onychomycosis (nail fungus). Pursuant to the terms of the licensing agreement with Novartis, NexMed will be entitled to a milestone payment early next year. NexMed entered into an exclusive, worldwide agreement with Novartis in September 2005, under which Novartis assumed all clinical development, regulatory, manufacturing and commercialization responsibilities for NM10060.

NM100060 is a topical application of Lamisil(R) (terbinafine), formulated with terbinafine and the Company's patented NexACT permeation enhancer, which facilitates the delivery of the drug into the nail bed, where the fungus resides.

About NexMed

NexMed, Inc. is an emerging drug developer that is leveraging its proprietary drug technology to develop a significant pipeline of innovative pharmaceutical products to address significant unmet medical needs. The Company is also working with various pharmaceutical companies to explore the incorporation of NexACT(R) into their existing drugs as a means of developing new patient-friendly transdermal products and extending patent lifespans and brand equity. For further information about the Company, go to www.nexmed.com.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to its ability to maintain reduced expenditures, enter into partnering agreements, pursue growth opportunities, and/or other factors, some of which are outside the control of the Company.

Contact

NexMed, Inc.
Linda Burns, 609-371-8123, ext: 184
Senior Director Corporate Relations
lburns@nexmed.com
or
Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com


'"/>




Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research and ... Size, Share, Development, Growth and Demand Forecast to 2022" report to ... The global ... expected to grow at a CAGR of 6.7% during 2016-2022 ... segment held the largest share in the global market in 2015. Among ...
(Date:3/24/2017)... March 24, 2017 FinancialBuzz.com News Commentary  ... According ... of cannabis market research, the legal cannabis market is projected ... 2021, despite conflicting signals from the current presidential administration. The ... the two biggest drivers of growth in this industry are ...
(Date:3/24/2017)... 24, 2017 Global Ampoules Market ... definitions, classifications, applications and industry chain structure. The Ampoules ... development history, competitive landscape analysis, and major regions, development ... ... 105 pages providing 10 company profiles and 183 tables ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards for ... spectrum of disordered eating, announced today that the 2017 Symposium set a new attendance ... several countries converged on the Green Valley Resort in Las Vegas. , “We ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... wanted to create a communications platform that positions them as the go-to thought ... ONS reinvented their online publication as an always-on, always-fresh news, views and advocacy ...
(Date:3/24/2017)... ... March 24, 2017 , ... Viewers who like to educate themselves on current ... practices, goods, services, and societal issues tend to appreciate and love the "Informed" series, ... of utilizing running events for causes around the world. , Running for ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ Through ... a devotional journal chronicling the writer’s path toward true communion with God. “Finding ... God #TruthwithGrace” is the creation of published author Lea Michelle Johnson, a follower ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
Breaking Medicine News(10 mins):